18 December 2023
18 December 2023
After a pivotal vaccine trial failed earlier this year, research into treatment and prevention of HIV continues to be vital.
Following a data monitoring committee analysis, the company concluded that the trial was unlikely to meet its primary endpoints.
People aged 20 years or above and who have received two or more doses of an approved Covid-19 vaccine will be part of the trial.
Sensorion is also evaluating SENS-401 in patients to prevent residual hearing loss following cochlear implantation.
YolTech’s genome editing candidate YOLT-20, is being developed to treat hereditary transthyretin amyloidosis with cardiomyopathy.
The company has filed an application with the Bellberry HREC in Australia to begin a Phase III trial of CBL-514 for fat reduction.
ISP-001 has received orphan drug designation and rare paediatric disease designations from the US Food and Drug Administration (FDA) for MPS I treatment.
Already partnered with Janssen Research & Development in 2023, Atropos Health links with Seqster to target underrepresented groups in research.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
